Femme Homme
- | Pays :
- Russian Federation
- India
- Ukraine
- ...
- | Organes : -
- | Spécialités : -
Extrait
BCD-022-02 is a double-blind randomized clinical trial comparing efficacy of BCD-022 (INN: trastuzumab) and paclitaxel to Herceptin and paclitaxel in HER2-positive metastatic breast cancer with pharmacokinetics substudy. The purpose of the study is to demonstrate the non-inferiority of efficacy and safety of BCD-022 compared to Herceptin. Also study includes pharmacokinetics assessment.
Critère d'inclusion
- Human Epithelial Receptor (HER)-2 Positive Breast Cancer